论文部分内容阅读
目的:探讨新型雌激素受体GPR30在子宫内膜样腺癌组织中表达及其临床意义。方法:采用免疫组织化学对40例不同分化级别的子宫内膜癌组织中GPR30进行了定位研究,随机选取GPR30免疫组化阳性的不同分化级别子宫内膜癌组织各5例,进行了原位杂交实验;采用图像分析技术研究其相对定量。结果:GPR30免疫反应阳性物质主要位于腺癌细胞质内,细胞核阴性;高分化子宫内膜样腺癌GPR30阳性表达率为66.7%(12/18),低分化组为77.8%(7/9),两者差异有统计学意义,P<0.05;随着子宫内膜样腺癌分化程度的降低,GPR30mRNA杂交信号物质的相对含量也逐渐增强,相邻各组间差异有统计学意义,P<0.01。结论:GPR30可能参与了子宫内膜样腺癌增殖与分化的调节。
Objective: To investigate the expression of novel estrogen receptor GPR30 in endometrioid adenocarcinoma and its clinical significance. Methods: Immunohistochemistry was used to study the localization of GPR30 in 40 cases of endometrial carcinoma with different differentiation levels. Five cases of endometrial carcinoma with different differentiation grade were selected randomly from the group of GPR30 immunohistochemistry. Experiments; image analysis techniques to study the relative quantification. Results: GPR30 immunoreactive positive cells mainly located in the cytoplasm of adenocarcinoma, with negative nuclei. The positive rate of GPR30 expression in well-differentiated endometrioid adenocarcinoma was 66.7% (12/18), poorly differentiated group was 77.8% (7/9) The difference between the two groups was statistically significant (P <0.05). With the decrease of the degree of differentiation of endometrial adenocarcinoma, the relative content of GPR30 mRNA hybridization signal substance also gradually increased, with significant difference between adjacent groups (P <0.01) . Conclusion: GPR30 may be involved in the regulation of proliferation and differentiation of endometrial adenocarcinoma.